Condition

Biliary Tract Cancer clinical trials and research

• 55Clinical trials
• 2NIH research projects
• 41Countries

Newest Biliary Tract Cancer clinical trials

All recruiting trials (55)

• Sintilimab with NALIRIFOX or GP as first-line treatment for metastatic biliary tract cancer

  This study tests whether adding sintilimab to either NALIRIFOX or gemcitabine‑cisplatin can help people with metastatic biliary tract cancer who have not had prior systemic therapy.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07831993

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Liposomal irinotecan with 5-FU/LV and sintilimab plus SBRT for unresectable biliary tract cancer

  This trial tests whether combining liposomal irinotecan, 5-FU/LV, and sintilimab, followed by SBRT, can help patients with unresectable locally advanced biliary tract cancer become eligible for surgery or slow disease progression.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07797816

• Futibatinib and immunotherapy with chemo as first-line treatment for advanced biliary tract cancer

  A first-line treatment test combines Futibatinib with Zimberelimab and Gemcitabine/Cisplatin to see if it improves survival in people with unresectable or advanced biliary tract cancer.

  Recruiting at 4 sites Phase 3 Taiho Pharmaceutical Co., Ltd. · Brisbane and 20 other locations · NCT07710885

• ctDNA-guided precision care for lung, GIST, colorectal, biliary, and ovarian cancers

  This trial tests a blood test that looks for tumor DNA in patients with several cancers to help guide personalized treatment decisions.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07673861

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

• First-line chemo with hepatic arterial infusion plus Envafolimab and Lenvatinib for unresectable biliary tract cancer

  This trial tests a first-line treatment combining hepatic arterial infusion chemotherapy with Envafolimab and Lenvatinib to see if it helps patients with unresectable biliary tract cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07636798

• BL-M07D1 vs physician’s choice chemotherapy after platinum failure in HER2-positive biliary tract cancer

  This Phase 3 trial tests BL-M07D1 against the doctor’s choice chemotherapy in adults with HER2-expressing biliary tract cancer that has progressed after platinum therapy.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Hefei, Anhui and 1 other locations · NCT07606599

• BL-B01D1 vs physician’s choice in biliary tract cancer after platinum failure

  This phase 3 trial tests whether BL-B01D1 helps patients with locally advanced or metastatic biliary tract cancer who have already had platinum-based chemotherapy fail, compared with the doctor’s choice treatment.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07582315

• Alternating liver-artery and IV chemotherapy with optional adebrelimab and apatinib for unresectable biliary tract cancer

  This study will test whether alternating hepatic arterial infusion chemotherapy and standard IV gemcitabine–cisplatin, with or without the immunotherapy adebrelimab and the targeted drug apatinib, helps people with unresectable biliary tract cancer shrink tumors and live longer.

  Recruiting Phase 2 Air Force Military Medical University, China · Xi'an, Shaanxi · NCT07569679

• Trastuzumab plus serplulimab with chemotherapy for HER2-positive advanced biliary tract or urothelial cancer after prior therapy

  This study will test whether adding trastuzumab and serplulimab to chemotherapy helps people with HER2-positive unresectable or metastatic biliary tract cancer or urothelial carcinoma who have not responded to standard treatment.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07506057

• SHR-A1904 for advanced biliary tract cancer after prior systemic treatment failure

  This trial will test whether the experimental drug SHR-A1904 can help people with advanced or metastatic biliary tract cancer whose prior systemic treatments failed and whose tumors express CLDN18.2.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07450976

• Ivosidenib plus lenvatinib or PD‑1/PD‑L1 therapy for IDH1‑mutant advanced biliary tract cancer

  This trial will try combining ivosidenib with either lenvatinib or a PD‑1/PD‑L1 immunotherapy in people with advanced biliary tract cancer who have an IDH1 mutation and whose disease progressed after chemotherapy.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07282262

• Neoadjuvant Tuvonralimab and Iparomlimab with GEMOX for resectable biliary tract cancer

  This trial tests whether giving Tuvonralimab and Iparomlimab together with GEMOX chemotherapy before surgery helps adults with resectable or borderline-resectable biliary tract cancer get better surgical and pathologic outcomes.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07267078

• Rilvegostomig or durvalumab with gemcitabine–cisplatin for first-line biliary tract cancer

  This compares rilvegostomig plus gemcitabine–cisplatin to durvalumab plus gemcitabine–cisplatin as first treatment for people with advanced biliary tract cancer.

  Recruiting at 153 sites Phase 3 AstraZeneca · Birmingham, Alabama and 182 other locations · NCT07221253

• MiniPDX-guided postoperative adjuvant therapy for biliary tract cancer

  This will test whether using a MiniPDX drug-sensitivity test on a patient’s tumor can guide post-surgery chemotherapy for people with biliary tract cancer.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07156058

• Blood-based ctDNA testing to find genetic changes in advanced biliary tract cancer

  This project will test whether a blood test called ctDNA can find actionable genetic changes like FGFR2 fusions and IDH1 mutations in people with advanced or metastatic biliary tract cancer.

  Recruiting CHA University · Seongnam-si, Gyeonggi-do · NCT07151118

• Blood ctDNA testing to find genetic changes in advanced biliary tract cancer

  This project tests whether a blood test that looks for tumor DNA can reliably find targetable genetic changes in people with advanced biliary tract cancer and help guide treatment choices.

  Recruiting CHA University · Seongnam-si, Gyeonggi-do · NCT07142226

• Adebrelimab with apatinib plus gemcitabine–cisplatin for initially unresectable biliary tract cancer

  This trial tests whether adding the immunotherapy adebrelimab and the targeted drug apatinib to standard chemotherapy helps people with newly diagnosed, unresectable biliary tract cancer.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07135544

• Trastuzumab plus chemotherapy versus chemotherapy alone for first-line HER2-positive advanced biliary tract cancer

  This trial will test if adding trastuzumab to standard first-line chemotherapy helps people with HER2-positive advanced or metastatic biliary tract cancer control their disease longer than chemotherapy alone.

  Recruiting at 3 sites Phase 3 Tata Memorial Centre · Muzaffarpur, Bihar and 5 other locations · NCT07062263

• Anti-blood-vessel therapy after immunotherapy for advanced bile duct or gallbladder cancer.

  This study will test whether giving the anti-angiogenic drug anlotinib after first-line immunotherapy helps people with advanced bile duct or gallbladder cancer live longer without their disease getting worse.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07025174

• Evaluating MT-4561 in Patients with Advanced Solid Tumors

  This study is testing a new drug called MT-4561 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 6 sites Phase 1/2 Tanabe Pharma America, Inc. · Los Angeles, California and 5 other locations · NCT06943521

• AK130 with AK112 for advanced biliary tract cancer

  This trial will test whether combining AK130 with AK112, or using AK112 alone, is safe and helps people with advanced biliary tract cancer who have not responded to first-line therapy.

  Recruiting Phase 1/2 Akeso · Beijing, Beijing Municipality · NCT06938321

• CAR-T therapy targeting CDH17 for advanced solid tumors

  This study is testing a new CAR-T cell therapy aimed at treating advanced solid tumors that have a specific marker called CDH17 in patients who have run out of other treatment options.

  Recruiting Early Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT06937567

• Helicobacter infections and biliary tract cancers

  This study will test whether Helicobacter bacteria (H. pylori, H. bilis, H. hepaticus) are more common in people with biliary tract cancers than in people with benign gallbladder conditions or healthy liver donors.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT06909188

• Tasfygo for unresectable FGFR2‑fusion biliary tract cancer after chemotherapy

  This study will see if Tasfygo is safe for people with unresectable biliary tract cancer who have an FGFR2 fusion and whose disease progressed after chemotherapy.

  Recruiting Eisai Inc. · Tokyo · NCT06793709

• Combining Ligufalimab and Cadonilimab for Advanced Liver Cancers

  This study is testing if combining two treatments, Ligufalimab and Cadonilimab, can help people with advanced liver cancers that haven't improved with other therapies.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT06789848

• Evaluating pain management methods for minimally invasive cancer surgery

  This study is testing which pain management method works best for people undergoing minimally invasive cancer surgery by comparing three different approaches.

  Recruiting Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT06731998

• Combination treatment for advanced solid tumors

  This study is testing a new combination treatment for people with advanced solid tumors, like biliary tract cancer and melanoma, to see if it works better than standard therapies for those who haven't had success with them.

  Recruiting Phase 1/2 Hangzhou Hanx Biopharmaceuticals, Ltd. · Beijing, Beijing Municipality · NCT06708663

• Using mitochondrial DNA in blood to monitor biliary tract cancer recurrence

  This study is testing if checking for changes in mitochondrial DNA in blood can help doctors see if biliary tract cancer comes back after treatment.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06653127

• Evaluating biomarkers in advanced biliary tract cancer treatment with lenvatinib and pembrolizumab

  This study is testing if a combination of two drugs, lenvatinib and pembrolizumab, can help people with advanced biliary tract cancer and is looking for clues in their genetic data to see how well the treatment works.

  Recruiting CHA University · Seongnam-si, Gyeonggi-do · NCT06648057

• Treatment of advanced biliary tract tumors with HRS-4642 alone or with adebrelimab

  This study is testing if a new treatment called HRS-4642, alone or with another drug called adebrelimab, can help people with advanced biliary tract cancer who haven't had success with other treatments.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06620848

• Combining chemotherapy, immunotherapy, radiation, and heat treatment for advanced biliary tract cancer

  This study is testing a new combination of chemotherapy, immunotherapy, radiation, and heat treatment to see if it can help people with advanced biliary tract cancer who can’t have surgery.

  Recruiting at 2 sites Phase 1 University of Maryland, Baltimore · Baltimore, Maryland and 1 other locations · NCT06546969

• Ivonescimab versus FOLFOX for advanced biliary tract cancer

  This trial will test whether ivonescimab works better than standard FOLFOX chemotherapy for people with advanced biliary tract cancer after their first treatment stopped working.

  Recruiting at 17 sites Phase 2 Unicancer · Amiens and 41 other locations · NCT06529718

• Comparing T-DXd with Rilvegostomig to Standard Treatment for Advanced HER2-expressing Biliary Tract Cancer

  This study is testing if a new combination treatment for advanced biliary tract cancer can work better than the usual options for adults with this condition.

  Recruiting at 232 sites Phase 3 AstraZeneca · Scottsdale, Arizona and 271 other locations · NCT06467357

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Treatment of HER2-positive Biliary Tract Cancer with TQB2102

  This study is testing a new injection called TQB2102 to see if it can help people with advanced HER2-positive biliary tract cancer who haven't had success with other treatments.

  Recruiting at 2 sites Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuyang, Anhui and 42 other locations · NCT06431490

• Treatment for advanced gastrointestinal cancers using MK-2870 with or without chemotherapy

  This study is testing whether a new drug called MK-2870, alone or with chemotherapy, can help people with advanced gastrointestinal cancers like colorectal, pancreatic, or biliary tract cancer feel better and improve their treatment outcomes.

  Recruiting at 30 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 54 other locations · NCT06428409

• Evaluating BL-M07D1 for HER2 Expressing Solid Tumors

  This study is testing a new treatment called BL-M07D1 to see if it is safe and effective for people with advanced solid tumors that have a specific protein called HER2 after they have tried other treatments.

  Recruiting at 24 sites Phase 1 SystImmune Inc. · Birmingham, Alabama and 25 other locations · NCT06293898

• Zanidatamab combined with standard therapy for advanced HER2-positive biliary tract cancer

  This study is testing if a new treatment combining Zanidatamab with standard chemotherapy can help people with advanced HER2-positive biliary tract cancer feel better and live longer.

  Recruiting at 69 sites Phase 3 Jazz Pharmaceuticals · Duarte, California and 184 other locations · NCT06282575

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• Treatment with AZD0901 for advanced solid tumors expressing Claudin18.2

  This study is testing a new treatment called AZD0901 for people with advanced solid tumors that have a specific protein, to see if it works better alone or with other chemotherapy drugs.

  Recruiting at 44 sites Phase 2 AstraZeneca · Orange, California and 51 other locations · NCT06219941

• Using blood tests to manage gastrointestinal tumors

  This study is testing if blood tests that look for tumor DNA can help doctors better manage patients with gastrointestinal tumors like pancreatic, colon, and biliary tract cancers.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Lazio · NCT06202131

• Detecting early liver, biliary tract, and pancreatic cancers

  This study is trying to see if a new way of testing blood samples can help find early-stage liver, biliary tract, and pancreatic cancers in people who have cancer, those with benign diseases, and healthy individuals.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06139042

• Combination chemotherapy for patients with resectable biliary tract cancers

  This study is testing a new combination of chemotherapy drugs before surgery to see if it helps people with certain types of biliary tract cancers live longer without their cancer coming back.

  Recruiting at 2 sites Phase 2/3 Gruppo Oncologico del Nord-Ovest · Ancona and 18 other locations · NCT06037980

• Observational study on biliary tract cancer patients

  This study is trying to see if certain gene mutations in patients with biliary tract cancer can help predict how long they will live and how well they respond to treatment.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Rome · NCT05942807

• Combining TU2218 with KEYTRUDA for advanced solid tumors

  This study is testing a new treatment combining TU2218 and KEYTRUDA to see if it can help people with advanced solid tumors who haven't responded to other therapies.

  Recruiting at 8 sites Phase 1/2 TiumBio Co., Ltd. · San Antonio, Texas and 10 other locations · NCT05784688

• Evaluating RP2 with second-line therapy for advanced liver cancer

  This study is testing if a new treatment called RP2, used with two other medications, can help people with advanced liver cancer who haven't responded well to previous treatments.

  Recruiting at 12 sites Phase 2 Replimune, Inc. · Beverly Hills, California and 11 other locations · NCT05733598

• Precision medicine for liver and biliary cancers using genetic testing

  This study is testing if personalized treatments based on genetic testing can help people with liver and bile duct cancers live longer and feel better.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT05520788

• Evaluating Datopotamab Deruxtecan for Advanced Solid Tumours

  This study is testing a new cancer treatment called Datopotamab Deruxtecan to see how well it works and how safe it is for people with advanced solid tumors like ovarian and colorectal cancers.

  Recruiting at 56 sites Phase 2 AstraZeneca · Los Angeles, California and 95 other locations · NCT05489211

• Olaparib and Durvalumab for Biliary Tract Cancer after Chemotherapy

  This study is testing if the drugs Olaparib and Durvalumab can help people with advanced biliary tract cancer who have finished their first round of chemotherapy and have certain gene mutations.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT05222971

• Finding new biomarkers for biliary tract cancer and gallbladder cancer

  This study is trying to find new markers in blood and tissue samples from patients with biliary tract and gallbladder cancer to help doctors diagnose the disease earlier and predict how well treatments will work.

  Recruiting Herlev and Gentofte Hospital · Herlev, Copenhagen · NCT05184400

• Evaluating the safety of AB122 in patients with advanced solid tumors

  This study is testing a new drug called AB122 to see if it's safe for people with advanced solid tumors like pancreatic, colorectal, lung, and gastric cancers.

  Recruiting at 9 sites Phase 1 Taiho Pharmaceutical Co., Ltd. · Aichi and 8 other locations · NCT04999761

• Identifying markers to predict treatment response in bile duct cancer

  This study is trying to find markers that can help doctors predict how well different treatments will work for people with bile duct cancer.

  Recruiting at 32 sites GERCOR - Multidisciplinary Oncology Cooperative Group · Amiens and 31 other locations · NCT04935853

• Using virtual reality to help manage pain in GI cancer patients

  This study is testing if virtual reality can help people with GI cancer manage their severe abdominal pain better than standard treatments.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT04907643

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Blood metabolites to find biomarkers for biliary tract cancer risk

  A large study will test blood metabolites to identify markers that may indicate future risk of biliary tract cancer in people from diverse populations.

  NIH research Vanderbilt University Medical Center · Nashville, United States · NIH-11303273

• Identifying blood markers that indicate risk for biliary tract cancer

  This study is looking at blood samples to find signs that could help predict the risk of biliary tract cancer, like gallbladder and bile duct cancers, so if you're asked to join, your contribution could help spot this cancer earlier for others.

  NIH research Vanderbilt University Medical Center · Nashville, United States · NIH-11078721

Related topics

Quick answers

How many Biliary Tract Cancer clinical trials are recruiting right now?

55, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 41 countries. The most sites are in China (28 trials), United States (17 trials), South Korea (12 trials), Japan (10 trials), Italy (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 16, Phase 1/2: 9, Phase 3: 7, Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →